ClinicalTrials.gg

TargetBeta

GRIN2A

glutamate ionotropic receptor NMDA type subunit 2A · also GluN2A, NR2A, NMDAR2A · Glutamate ionotropic receptor NMDA type subunits

3 programs in company-led studies act on GRIN2A, from 3 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
EsketamineruleJohnson & Johnsonphase 4512 runningGRIN1, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3BChEMBL
DextromethorphanruleOtsukaphase 4151 runningSIGMAR1ChEMBL
MemantineruleAbbViephase 4290 runningGRIN1, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3BChEMBL

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.